ea0049gp123 | Endocrine Tumours | ECE2017
Terzolo Massimo
, Basile Vittoria
, Megerle Felix
, Hermann Wiebke
, Cicciarella Federica
, Libe Rossella
, Baudin Eric
, Haak Harm
, Mannelli Massimo
, Boscaro Marco
, Quinkler Marcus
, Bourdeau Isabelle
, Perotti Paola
, Hahner Stefanie
, Beuschlein Felix
, Fassnacht Martin
Background: Adjuvant mitotane therapy is frequently used in Europe following surgery for adrenocortical carcinoma (ACC). Management of adjuvant mitotane is mainly empirical and a major open question is the optimal duration of therapy, because no study has ever addressed this issue.Objective: We aimed to assess the outcome of ACC patients who were treated with adjuvant mitotane for at least one year following surgery and then discontinued therapy for othe...